Cytokine inhibition in severe asthma: Current knowledge and future directions

Current Opinion in Pulmonary Medicine

Volumn 17, Issue 1, 2011, Pages 29-33

  Corren, Jonathan ^a  

^a Allergy Medical Clinic   (United States)

Author keywords

asthma; cytokine; monoclonal antibodies; receptor antagonists

Indexed keywords

AMG 317; BENRALIZUMAB; CYTOKINE RECEPTOR ANTAGONIST; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; INTERLEUKIN 9; LEBRIKIZUMAB; MEDI 528; MEPOLIZUMAB; PITRAKINRA; PLACEBO; TRALOKINUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; ARTICLE; ASTHMA; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG TUBERCULOSIS; NONHUMAN; PNEUMONIA; PROFESSIONAL KNOWLEDGE; SEPSIS; TH2 CELL;

ANTIBODIES, MONOCLONAL; ASTHMA; HUMANS; INTERLEUKINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650515905     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283413105     Document Type: Article

References (13)

1. Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107:963-970.
2. Hart TK, Blackburn MN, Brigham-Burke M, et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized antiinterleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 2002; 130:93-100.
3. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006; 354:697-708.
4. Erin EM, Leaker BR, Nicholson GC, etal. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 2006; 174:753-762.
5. Wenzel SE, Barnes P, Bleecker ER, et al. A randomized, double-blind placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009; 179:549-558.
6. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176:1062-1071.
7. Haldar P, Brightling CE, Hargadon B, etal. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973-984.
8. Nair P, Pizzichini MM, Kjarsgaard M, etal. Mepolizumab for prednisone-depen-dent asthma with sputum eosinophilia. N Engl J Med 2009; 360:985-993.
9. Wenzel S, Wilbraham D, Fuller R, etal. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370:1422-1431.
10. Corren J, Busse W, Meltzer EO, etal. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010; 181:788-796.
11. Antoniu SA. MEDI-528, an anti-IL-9 humanized antibody for the treatment of asthma. Curr Opin Mol Ther 2010; 12:233-239.
12. He R, Geha RS. Thymic stromal lymphopoietin. Ann N Y Acad Sci 2010; 1183:13-24.
13. Alcorn JF, Crowe CR, Kolls JK. TH17 cells in asthma and COPD. Annu Rev Physiol 2010; 72:495-516.